Nautilus Biotechnology’s Co-Founder and CEO Sujal Patel will participate in a panel at the Biocom Converge Summit this Thursday, April 23, at 11:40am PT.
The discussion will examine the transformative role of artificial intelligence tools in the biotechnology industry, with leaders including Jacob Berlin, PhD, Co-Founder and CEO of Terray Therapeutics, joining the conversation.
Nautilus Biotechnology recently launched its Voyager Platform and announced its first customers through the Iterative Mapping Early Access Program, according to a company statement. The firm has also outlined how statistics and artificial intelligence are advancing holistic understanding in proteomics research in an earlier briefing. These initiatives highlight the company’s ongoing focus on AI-driven biotechnology applications.
This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.